KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

BeOne Medicines (ONC) Equity Average (2016 - 2025)

BeOne Medicines (ONC) has disclosed Equity Average for 10 consecutive years, with $4.2 billion as the latest value for Q4 2025.

  • On a quarterly basis, Equity Average rose 25.45% to $4.2 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $4.2 billion, a 25.45% increase, with the full-year FY2025 number at $3.8 billion, up 11.99% from a year prior.
  • Equity Average was $4.2 billion for Q4 2025 at BeOne Medicines, up from $3.9 billion in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $6.0 billion in Q1 2022 to a low of $3.4 billion in Q2 2024.
  • A 5-year average of $4.1 billion and a median of $3.9 billion in 2021 define the central range for Equity Average.
  • Peak YoY movement for Equity Average: surged 107.77% in 2021, then fell 28.27% in 2023.
  • BeOne Medicines' Equity Average stood at $4.7 billion in 2021, then decreased by 4.75% to $4.5 billion in 2022, then dropped by 19.23% to $3.7 billion in 2023, then dropped by 7.29% to $3.4 billion in 2024, then grew by 25.45% to $4.2 billion in 2025.
  • Per Business Quant, the three most recent readings for ONC's Equity Average are $4.2 billion (Q4 2025), $3.9 billion (Q3 2025), and $3.6 billion (Q2 2025).